Európska únia - slovenčina - EMA (European Medicines Agency)

merck sharp & dohme b.v. - elbasvir, grazoprevir - hepatitída c, chronická - direct acting antivirals, antivirals for systemic use, antivirals for treatment of hcv infections - zepatier is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg (see sections 4. 2, 4. 4 a 5. pre vírusom hepatitídy c (hcv) genotyp-konkrétne aktivity pozri časť 4. 4 a 5.

Európska únia - slovenčina - EMA (European Medicines Agency)

gedeon richter - kariprazín hydrochlorid - schizofrénie - psycholeptika - reagila je indikovaná na liečbu schizofrénie u dospelých pacientov.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

astellas pharma s.r.o., Česká republika - takrolimus - 59 - immunopraeparata

Európska únia - slovenčina - EMA (European Medicines Agency)

pfizer europe ma eeig - glasdegib maleate - leukémia, myeloidná, akútna - antineoplastické činidlá - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

Európska únia - slovenčina - EMA (European Medicines Agency)

blueprint medicines (netherlands) b.v. - avapritinib - gastrointestinálne stromálne nádory - iné antineoplastické činidlá, protein kinase inhibítory - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

Európska únia - slovenčina - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinálne stromálne nádory - antineoplastické činidlá - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Európska únia - slovenčina - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - imunosupresíva - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).

Európska únia - slovenčina - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - maribavir - cytomegalovírusové infekcie - antivirotiká na systémové použitie - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). je treba vziať do úvahy oficiálne usmernenie o vhodnom používaní protivírusové agentov.

Európska únia - slovenčina - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - neoplazmy prsníkov - endokrinná terapia - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Európska únia - slovenčina - EMA (European Medicines Agency)

merck sharp dohme limited - lamivudine, raltegravir draslíka - hiv infekcie - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - dutrebis je indikovaný v kombinácii s inými anti‑retroviral liekmi na liečbu infekcie vírusom ľudskej imunitnej nedostatočnosti (hiv‑1) u dospelých, dospievajúcich a detí vo veku 6 rokov a vážiacej najmenej 30 kg bez súčasnosti alebo minulosti dôkazy o vírusovej rezistencii voči antivirotík inštitúcií (inhibítorprenosu reťazcov integrázou) a nrti (nukleozidový inhibítor reverznej transkriptázy) tried (pozri časti 4. 2, 4. 4 a 5.